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Available online 3 July 2014Abstract This study aimed at evaluating the usefulness of a structured patient counseling program
on clinical outcomes of asthma patients in Saudi Arabia. This cross sectional study enrolled 10
asthma patients and all were evaluated for their baseline knowledge on asthma, quality of life, com-
pliance, patient satisfaction and drug related problems among randomly selected 5 (of the total 10)
patients. The median (IQR) age of the patients was 46 (33.5–56.2) years. The baseline knowledge
scores was 9 (8–11), the maximum possible scores to be 21. Cronbach alpha of the KQ was 0.65.
The overall total median (IQR) compliance (Morisky) score was 4 (3–5), the maximum possible score
was 5. The patient satisfaction median (IQR) score was 35.5 (32–46.25), the maximum possible score
was 70. Of the total patients 3 (30%) had a history of allergy. There were total 18 allergens observed in
these patients. There has been no drug–drug or drug–food interactions observed between among the
prescribed drugs of the patients. Altogether 2 patients reported a total of 2 ADRs. The knowledge of
the asthma patients was found to be poor. Missing the dose was the most commonly encountered
drug taking behavior. The compliance was found to be good and the patient satisfaction was average.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Asthma is a chronic condition characterized by reversible air-
way obstruction, airway inﬂammation and increased airway
responsiveness to a variety of stimuli. In the recent past Saudi
Arabia has witnessed an increase in asthma (Al Frayh et al.,
2001). There is also a known link between genetic natures of
individuals with asthma in the country (Bener et al., 1992).
Asthma being a chronic disease requiring special care often
needs lifelong medicines and care that even go beyond the
institutional care. In addition to drug therapy, several non-
pharmacological measures like smoking cessation, avoidance
Table 1 Demographic distribution of the patients (n= 10).
Parameters Variables n %
Age median (IQR) age = 46
(33.5–56.2) years
Less than 30 0 0
30–60 9 90
More than 60 1 10
Gender Male 5 50
Female 5 50
Educational level Primary 2 20
Secondary 5 50
Intermediate 0 0
University 3 30
Employment status Government 8 80
Others 2 20
Smoking Yes 3 30
No 7 70
History of allergy Yes 3 30
No 7 70
Duration of asthma Less than 5 years 5 50
5–10 years 3 30
More than 10 years 2 20
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asthma patients. Similarly, the improper use of inhalation
devices is known to be one of the causes of therapeutic failure
(Newman et al., 1991). Similarly, self monitoring of treatment
is essential in asthma so that the patient himself/herself
becomes an active partner of self-care. Pharmacist being an
important healthcare professional is expected to play an
important role in chronic disease management (Lewis et al.,
1997) as documented by various researchers worldwide
(Cordina et al., 2001; De Tullio and Corson, 1987; Bynum
et al., 2001; Odegard et al., 2004; Weinberger et al., 2002).
In Saudi Arabia, the concept of pharmaceutical care is new
and pharmacists are yet to contribute substantially in provid-
ing patient counseling and education. This preliminary study
was conducted to evaluate the knowledge and quality of life,
identify the types of drug therapy related problems, compli-
ance and satisfaction of asthma patients. Pharmacist can be
an important member of a healthcare team and can contribute
for the better therapeutic outcome management and decrease
the number of drug related problems in asthma patients
(Narhi et al., 2000).
2. Methodology
A cross sectional study was conducted among 10 asthma
patients attending the chest clinic at the King Saud hospital
in Onaizah, Saudi Arabia during May–June 2013. These study
subjects were selected among the asthma patients attending the
chest clinic and after ﬁlling a written informed consent. Upon
enrollment the demographic data were obtained using patient
proﬁle form, the baseline knowledge on asthma using knowl-
edge questionnaire, the baseline Quality of life (using AQLQ
questionnaire, adopted with permission from authors), and
patient compliance, satisfaction and drug taking behavior were
evaluated. The compliance was evaluated using a Morisky
scale and the patient satisfaction on the pharmacist services
using a satisfaction questionnaire. Similarly the drug related
problems encountered by 5 randomly selected patients were
also assessed. All patient data were entered in SPSS program
and appropriate analysis has been made as per the study.
Descriptive statistics was performed for the demographic vari-
ables and scores. The entire research process has been
approved by the Al Qassim research ethics committee.
3. Results
3.1. Demography distribution of the patients (n= 10)
Altogether 10 patients with median (IQR) age of 46 (33.5–
56.2) were enrolled in the study. A higher percentage of the
respondents were in the age group 30–60 years with an equal
proportion (50% each) of gender distribution. The demo-
graphic details of the study subjects are tabulated in Table 1.
3.1.1. Baseline knowledge evaluation of the respondents
(n = 10)
Of the total 21 questions, the questions Q10 (Which factor can
worsen asthma condition?) and Q 19 (Can the same medicines
be shared by two or more asthma patients?) are answered by
all the respondents. Similarly 90% of the respondentsanswered Q8 (Can asthma spread from one individual to other
by physical contact?) and Q21 (What are the strategies that can
be followed by asthma patients so as to have a healthy life?)
correctly. The baseline evaluation of knowledge scores
revealed the total score to be 9 (8–11), and the maximum pos-
sible score to be 21. The median (IQR) total scores of the indi-
vidual responses are listed in Table 2.
3.1.2. Baseline evaluation of the compliance of the respondents
(n = 10)
The overall total median (IQR) Morisky score was 4 (3–5), and
the maximum possible score was 5. The scores of the individual
responses are tabulated in Table 3.
3.1.3. Baseline evaluation of the patient satisfaction (n = 10)
The patient satisfaction on the care given by the pharmacist
was analyzed and is tabulated in Table 4. The total median
(IQR) score was 35.5 (32–46.25), and the maximum possible
score was 70.
3.1.4. Baseline quality of life analysis (n = 10)
The QoL of the study subjects at baseline was studied and the
results are displayed in Table 5.
3.1.4.1. Analysis of drug related problems (n = 5). Of the total
5 patients, 3 (60%) had a history of allergy. There were a total
of 18 allergens observed in these 5 patients. There were a total
of 11 drugs prescribed to the these 5 patients that include
Ammonium chloride (expectorant), budesonide (inhaled
corticosteroid), cefuroxime (Cephalosporin antibiotic), dextro-
methorphan (Expectorant), diphendydramine (Antihista-
minic), ﬂuticasone (Inhaled corticosteroid), formoterol
[bronchodilator (beta agonist)], paracetamol (antipyretic),
and salbutamol [(bronchodilator) (beta agonist)]. There has
been no drug–drug or drug–food interactions observed among
the prescribed drugs of the patients. Altogether 2 (40%)
patients reported ADRs. One of them reported allergy and
Table 2 Baseline knowledge scores of the respondents (n= 10).
Responses Median (IQR)
1. Which part of the body is aﬀected in an asthma patient? 0.5 (0–1)
2. Mention any one drug that should not be used by asthma patients 0 (0–0)
3. Mention any one advantage of using a Meter dose inhaler 0 (0–1)
4. Which is the ﬁrst step in using a meter dose inhaler? 1 (0–1)
5. While taking asthma medicines through an inhaler how long the patient should hold the
breath?
0 (0–0)
6. How long the patient should wait between two consecutive puﬀs? 0 (0–0)
7. Do you think asthma is completely curable? 0 (0–0.25)
8. Can asthma spread from one individual to other by physical contact? 1 (1–1)
9. Which one of the asthma medicine is given by inhalation route? 0(0–0)
10. Which factor can worsen asthma condition? 1 (1–1)
11. Can an asthma patient take painkiller without doctor/pharmacist advice? 1 (1–1)
12. Do you think the asthma medications are addictive? 1 (0–1)
13. Do you think using spacer is beneﬁcial to patients? 0.5 (0–1)
14. Do you know what is to be done if you miss a dose of the medication? 0.5 (0–1)
15 Do you know when asthma patients should stop taking their medicines? 0.5 (0–1)
16. How does one know the amount of medicine present inside a meter dose inhaler? 0 (0–0)
17. One of the following is a side eﬀect caused by inhalers containing corticosteroids 0 (0–0)
18. Mention one important precaution that needs to be taken by asthma patients so as to
prevent the occurrence of oral (topical) side eﬀects with corticosteroids?
0 (0–0)
19. Can the same medicines be shared by two or more asthma patients? 1(1–1)
20. Mr. A is taking ﬂuticasone inhaler for past 3 years for asthma control. He was traveling
to a remote place for holidays and forgot to take his medicine
a. Can he stop taking his inhaler medicine? 1 (0.75–1)
b. What happens if he stops taking it suddenly? 1 (0.5–1)
c. On normal conditions what precaution one should take while stopping Fluticasone
inhaler after longtime use?
0 (0–0)
21. What are the strategies that can be followed by asthma patients so as to have a healthy
life?
1 (1–1)
Cronbach alpha of the KQ was 0.65.
Table 3 Baseline evaluation of the compliance of the respondents (n= 10) [Morisky].
Responses Median (IQR) score
1. Do you sometimes forget to take your medicine? 1 (0–1)
2. People sometimes miss taking their medicines for reasons other than
forgetting. Thinking over the past 2 weeks, were there any days when you
did not take your medicine?
1 (0.5–1)
3. Have you ever cut back or stopped taking your medicine without telling
your doctor because you felt worse when you took it?
0 (0–0.5)
4. When you travel or leave home, do you sometimes forget to bring along
your medicine?
0 (0–1)
5. Did you take all your medicines yesterday? 0 (0–0.5)
6. When you feel like your symptoms are under control, do you sometimes
stop taking your medicine?
1 (0–1)
7. Taking medicine every day is a real inconvenience for some people. Do
you ever feel hassled about sticking to your treatment plan?
1 (0.5–1)
8. How often do you have diﬃculty in remembering to take all your
medicines?
0 (0–1)
212 A. Meshal et al.the other gastritis. However the exact cause has not been
known. The Naranjo score became 6.
3.1.4.2. Use of other (concurrent) medications (n = 5). Among
the 5, none of them had taken OTC medications and 4 (80%)
had taken herbal medicines and 2 (40%) experienced ADRs.None of them obtained treatment from other hospitals during
the time of enrollment in the study.
3.1.4.3. Drug taking behavior and problems (n = 5). Various
drug taking behaviors of the study subjects were analyzed. It
was important to note that 5 (100%) of the patients had missed
Table 4 Baseline evaluation of the patient satisfaction of the study subjects (n= 10).
Responses Median (IQR) score
1. Contents of the counseling process 2 (1.75–4.25)
2. Information leaﬂets provided by the Pharmacist 2.5 (1–4.25)
3. Information regarding the medicines provided by the Pharmacist 4 (1.75–4.25)
4. Counseling aids used by the Pharmacist 2.5 (1–4)
7. Medication calendar given by the Pharmacist 1 (1–4)
8. Information regarding the use of special devices 2.5 (1.75–4.25)
9. The verbal communication skills of the Pharmacist 4 (3.75–5)
10. The non-verbal communication skills of the Pharmacist 3.5 (3.75–4.25)
11. Usefulness of the counseling provided by the Pharmacist 3.5 (1.75–4.25)
12. Time management by the Pharmacist 3.5 (1–5)
13. Information regarding storage of medicines 1 (1–4)
14. Information regarding management of an emergency asthma attack. 1 (1–3)
Cronbach alpha of the SQ was 0.625.
Table 5 Baseline evaluation of the QoL of the study subjects.
Responses Median (IQR) score
1 4 (3.5–5.0)
2 6 4.75–6)
3 5.5 (4.75–6.25)
4 5 (4–6)
5 4.5 (3.75–6)
6 3.5 (3–5.25)
7 4 (3–5)
8 3 (2.75–4)
9 2.5 (2–4)
10 3 (2–4.25)
11 3 (2.75–5.25)
12 3 (2–4)
13 5 (3.75–6)
14 3.5 (2–4)
15 4 (3–5)
16 3 (2–3.25)
17 3 (2–3)
18 3.5 (2.75–4.25)
19 3 (2.75–4)
20 5 (4–6.25)
21 4 (3–5.5)
22 3.5 (3–4)
23 3 (2–4)
24 4.5 (4–5.25)
25 3.5 (3–5.25)
26 3 (2–3.25)
27 5 (4.5–6)
28 3 (2–4)
29 4.5 (4–5.25)
30 5 (4–6)
31 4.5 (3–5.25)
32 5 (4.75–6)
Table 6 Medication counseling problems.
Problems Number of patients Percentage
Disease not under control 5 100
Experienced side eﬀects/ADRs 2 40
Inadequate knowledge 4 80
Medication taking error 2 40
Compliance 1 20
Smoking 0
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have the problem of taking the drug unnecessarily, and 2
(40%) have irregular clinical appointment. None of the patient
has the problem of using contraindicated drug, drug interac-
tion and wrong drug.
3.1.4.4. List of medication counseling problems (n = 5). A total
of 5 patients had their disease not under control and 2 (40%)
experienced ADRs. More details regarding medication coun-
seling of subjects are as shown in Table 6.4. Discussion
The ﬁndings of the pilot study were instrumental in validating
the methodology and the study tools and also suggesting mod-
iﬁcations. Some of the interesting ﬁndings of the pilot study
were many of the patients were sensitive to or affected by dust
and perfume. Similarly most of the patients did not know the
medication name suggesting the need for counseling. Many of
the asthma patients also did not have the habit of using face
mask to protect from allergen. It was also important to note
that most of the study subjects avoid going to mosque due
to perfume used in mosque. The experience had also shown
that the patients in general preferred counseling to be provided
in a separate place and all the patients like to discuss regarding
his/her disease and drugs. It was also found that most of the
patients did not continue using their medication regularly.
It was also noticed that 60% of patients had history of
allergy. The common allergens are dust and perfume. Among
the patients, a total of 11 drugs were prescribed. These drugs
included inhale corticosteroids, expectorants, antibiotics etc.
There has been no drug–drug or drug–food interactions
observed among the prescribed drugs of the patients. Altogether
2 patients reported ADRs. One of them reported allergy and the
other gastritis. However the exact cause has not been known.
Among the 5 patients, none of themhad takenOTCmedications
and 4 (80%) had taken herbal medicines, and 2 (40%) experi-
enced ADRs. It was also found that all 5 patients had missed
the dose some time during the treatment and did not have their
disease under control and 2 (40%) experienced ADRs.
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This study included only the baseline evaluation of the param-
eters and hence do not include the ﬁndings of the impact of
intervention by the pharmacist.
6. Conclusion
The knowledge of the asthma patients was found to be poor,
suggesting the need for interventions. Missing the dose was
the most commonly encountered drug taking behavior. The
compliance was found to be good and the patient satisfaction
was average. Involvement of a pharmacist let counseling and
care program may be useful in improving all knowledge,
QoL, compliance and satisfaction of asthma patients. It can
in turn also improve the clinical outcomes of the patients.
7. Future directions
In the future, intervention can be carried out wherein the
impact of pharmacist providing counseling can be evaluated.
A large scale study can be carried out involving a large number
of patients and increasing the number of study areas.
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